Abstract
Modern Treatment of Chronic Heart Failure This article delves into the contemporary approaches to managing chronic heart failure (CHF), highlighting significant advancements in both medical and non-medical treatments. It covers:
- Pharmacological Therapies: Key drugs such as ACE inhibitors, ARBs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, which play crucial roles in improving heart function and patient outcomes.
- Device-Based Therapies: Technologies like Implantable Cardioverter Defibrillators (ICDs) and Cardiac Resynchronization Therapy (CRT) devices that assist in regulating heart rhythm and improving cardiac efficiency.
- Advanced Therapies: The use of Left Ventricular Assist Devices (LVADs) and heart transplantation for patients with severe heart failure, offering life-extending options.
- Lifestyle Modifications: The importance of diet, exercise, patient education, and self-management in controlling symptoms and improving quality of life.
- Emerging Therapies: Innovations in gene therapy, regenerative medicine, and novel pharmacological agents that hold promise for future treatments.
The article underscores the multifaceted nature of CHF treatment, combining established methods with cutting-edge research to enhance patient care and outcomes.
References
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., ... & Westlake, C. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. *Journal of the American College of Cardiology*, 70(6), 776-803. doi: 10.1016/j.jacc.2017.04.025
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & PARADIGM-HF Investigators and Committees. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. *New England Journal of Medicine*, 371(11), 993-1004. doi: 10.1056/NEJMoa1409077
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., ... & EMPEROR-Reduced Trial Investigators. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. *New England Journal of Medicine*, 383(15), 1413-1424. doi: 10.1056/NEJMoa2022190
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., ... & EMPHASIS-HF Study Group. (2011). Eplerenone in patients with systolic heart failure and mild symptoms. *New England Journal of Medicine*, 364(1), 11-21. doi: 10.1056/NEJMoa1009492
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., ... & Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure. *Journal of the American College of Cardiology*, 79(17), e263-e421. doi: 10.1016/j.jacc.2021.12.012
Ezekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., ... & Moe, G. W. (2017). 2017 Comprehensive update of the Canadian Cardiovascular Society guidelines for the management of heart failure. *Canadian Journal of Cardiology*, 33(11), 1342-1433. doi: 10.1016/j.cjca.2017.08.022
Writing Group Members, Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., ... & Turner, M. B. (2016). Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. *Circulation*, 133(4), 447-454. doi: 10.1161/CIR.0000000000000350